Arndt Vogel: First-in-Class EGFR-Directed KRAS G12V Inhibitor Shows Activity in Multiple Cancer Models
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X about a paper by Chad V. Pecot et al. published in Cancer Cell:
“A first-in-class EGFR-directed KRAS G12V selective inhibitor in Cancer Cell
EFTX-G12V selectively targets KRAS G12V while sparing wild-type KRAS
Activity in lung, colon, and PDAC cancer models
Very interesting MOA, KRAS is becoming draggable.”
Title: A first-in-class EGFR-directed KRAS G12V selective inhibitor
Authors: Lyla J. Stanland, Hayden P. Huggins, Snehasudha S. Sahoo, Alessandro Porrello, Yogitha Chareddy, Salma H. Azam, Jillian L. Perry, Pradeep S. Pallan, Kristina Whately, Lincy Edatt, William D. Green, Matthew C. Fleming, Jonah Im, Christina Gutierrez-Ford, Imani Simmons, Alyaa Dawoud, Katherine I. Zhou, Vandanaa Jayaprakash, Rani S. Sellers, Gabriela de la Cruz, Albert Wielgus, Justin Milner, Martin Egli, Albert A. Bowers, Chad V. Pecot.
You can read the Full Article in Cancer Cell.
More posts featuring Arndt Vogel.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023